Geneva, Aug. 6 -- International Clinical Trials Registry received information related to the study (NCT07737496) titled 'A Study of HW243040 in Healthy Participants' on July 27.

Study Type: Interventional

Study Design: Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Double (Participant, Investigator).

Primary Sponsor: Hubei Bio-Pharmaceutical Industrial Technological Institute Inc.

Condition: Healthy

Intervention: Drug: HW243040

Recruitment Status: Not recruiting

Phase: Phase 1

Date of First Enrollment: August 10, 2026

Target Sample Size: 98

Countries of Recruitment: China

To know more, visit https://clinicaltrials.gov/study/NCT07737496

Disclaimer: Curated by HT Synd...